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Structure-guided approaches to HIV-1 vaccine design depend on knowledge of the presentation of
neutralizing epitopes on gp120, such as the epitope for the broadly neutralizing mAb b12. Here, we
characterized predicted three-dimensional structures of functionally diverse gp120 proteins in their
b12-bound conformation, to better understand the gp120 determinants that expose or occlude the b12
epitope. Mapping the gp120–b12 binding interface identiﬁed amino acid polymorphisms within the C2,
C3, C4 and V5 regions of gp120 associated with augmented b12 binding, and importantly, identiﬁed
residues in the b12-exclusive binding domain of gp120 that are important for b12 neutralization
resistance. Structural studies suggest that these b12 resistance variants promote reduced conforma-
tional ﬂexibility in the b12 recognition site, which we show involves structural alterations within the
gp120 CD4 binding loop and the V4 loop. Together, our studies provide new mechanistic insights into
the gp120 determinants inﬂuencing sensitivity and resistance to HIV-1 neutralization by b12.
& 2012 Elsevier Inc. All rights reserved.Introduction
The envelope glycoprotein complex (Env) of human immuno-
deﬁciency virus type 1 (HIV-1) exists as a trimer of heterodimers,
comprising the surface gp120 glycoproteins non-covalently
linked to gp41 transmembrane glycoproteins that embed the
complex into the enveloping lipid bilayer (Chan et al., 1997;
Kwong et al., 2000a, 1998). The gp120 glycoprotein is primarily
responsible for interaction with host cell molecules used for viral
attachment and entry. The ﬁrst step in the HIV-1 entry process
involves gp120 binding to the CD4 molecule, which is a high
afﬁnity interaction that facilitates viral attachment (Dalgleish
et al., 1984). gp120 binds to CD4 via the Phe43 cavity, which isll rights reserved.
net Institute, 85 Commercial
ology, Burnet Institute, 85
Ramsland),a conserved hydrophobic pocket created by residues located
within the inner domain, bridging sheet and outer domain of
gp120 (Kwong et al., 1998; Wyatt et al., 1998). CD4 binding draws
the viral membrane into close proximity to the cellular mem-
brane via bending of a ﬂexible hinge region in CD4 (Sattentau,
1998). Conformational changes induced in gp120 as a result of
CD4 binding lead to the exposure of a binding site for one of the
chemokine coreceptors used for HIV-1 entry (Kwong et al., 1998;
Rizzuto et al., 1998; Sattentau and Moore, 1991; Wu et al., 1996;
Wyatt et al., 1995), which are either CCR5 or CXCR4 (Deng et al.,
1996; Dragic et al., 1996; Feng et al., 1996).
The gp120 protein consists of highly conserved inner and outer
domains, named for their relative position in the context of the
Env spike, as well as the bridging sheet which is a distinct
structure comprising elements from the inner and outer domains
(Kwong et al., 1998). The outer domain is exposed on the surface
of the Env trimer and has therefore evolved structural features
that protect gp120 from the humoral and cellular immune
responses (Kwong et al., 2002), including ﬁve highly variable
loops (named V1 through V5) and a heavily glycosylated surface.
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contains important immunological epitopes that are recognized
by the few highly potent and broadly neutralizing antibodies
discovered thus far (Wyatt et al., 1998; Wyatt and Sodroski,
1998), making the outer domain of particular interest for vaccine
development (Yang et al., 2004). The inner domain faces the
trimer axis and interacts with gp41 via the N- and C- termini
(Kwong et al., 1998, 2000b; Wyatt et al., 1998), and contains
receptor and coreceptor binding site structures that are highly
conserved amongst HIV-1 strains. The V1/V2 loops emanate from
distal strands of the inner domain and contribute to conforma-
tional masking of the CD4 and coreceptor binding sites (Kwong
et al., 1998, 2000b; Wyatt et al., 1993). The anti-parallel bridging
sheet forms a highly conserved structure that contains residues
critical for coreceptor binding that are exposed after binding to
CD4 (Kwong et al., 1998; Rizzuto et al., 1998; Thali et al., 1993;
Trkola et al., 1996a; Wu et al., 1996). Extensive glycosylation and
sequence variability within the loop regions enable HIV-1 to
evade the host immune response, and are particularly important
in protecting key target cell receptor binding sites from neutra-
lization by antibodies (Kozarsky et al., 1989; Kwong et al., 2002;
Wyatt et al., 1998).
The presentation of Env on the surface of the virion exposes
gp120 to a myriad of defence mechanisms by both the cellular
and humoral arms of the immune system. However, the majority
of antibodies targeting gp120 are ineffective at neutralizing HIV-1
infection (Burton et al., 1994; Wyatt et al., 1998). Crystallographic
analysis of gp120 in complex with the rare broadly neutralizing
antibody b12 has provided valuable insights into the nature of a
highly conserved neutralization epitope on gp120 (Zhou et al.,
2007). The b12 monoclonal antibody (mAb) binds to an epitope
that overlaps the CD4 binding site on gp120 (Burton et al., 1994;
McInerney et al., 1997), and can neutralize primary HIV-1 strains
from all HIV-1 subtypes (Burton et al., 1994; Trkola et al., 1995) as
well as protect macaques from vaginal challenge with chimeric
simian-HIV (SHIV) (Parren et al., 2001; Veazey et al., 2003). CD4
and b12 both bind predominantly to the same Env surface
exposed on the outer domain of gp120. However, b12 binds to
gp120 with greater afﬁnity than CD4, presumably because b12
grasps a highly conserved structure referred to as the CD4 binding
loop with all three loops of its heavy chain (Zhou et al., 2007).
In comparison, CD4 only binds to one side of the CD4 binding
loop. The angles of approach by CD4 and b12 are also slightly
different, resulting in binding epitopes that are distinct but which
have considerable overlap (Zhou et al., 2007). Moreover, cryo-
electron tomography studies of b12-bound trimeric Env com-
plexes showed that b12-induced conformational changes in
gp120 were less extensive than those induced by CD4 (Liu et al.,
2008). Another signiﬁcant difference between the b12 and CD4
binding sites involves the b20/b21 strand of gp120. The b20/b21
strand is one of the initial contact sites for CD4 and becomes part
of the bridging sheet after CD4-induced conformational changes
bring the b2/b3 strand of the inner domain and b20/b21 strand
into close proximity (Kwong et al., 1998). While previous muta-
genesis studies suggest that there is no appreciable effect of b20/
b21-strand mutations on gp120–b12 binding (Zwick et al., 2003),
more recent studies suggest a signiﬁcant effect of this gp120
region on b12 binding (Li et al., 2011). Together, these data
suggest that while the CD4 binding site and b12 epitope may
encompass some overlapping regions of gp120, they are also
independently modulated by different structures within gp120.
Although the b12-bound crystal structure of the CXCR4-using
HXB2 strain of gp120 has provided valuable insights into the
presentation of an important neutralizing epitope on gp120 (Zhou
et al., 2007), comparatively little is known about the structure and
presentation of this epitope on more clinically relevant CCR5-using(R5) gp120 proteins. Therefore, in this study we used homology
modeling to study the structural features of functionally diverse
and physiologically relevant primary R5 gp120 proteins in their
b12-bound state. These gp120 proteins have well characterized
functional phenotypes including fusogenicity, entry kinetics, the
efﬁciency and mechanism of CCR5 engagement, as well as exposure
of the CD4 binding site (Sterjovski et al., 2007,, 2011,, 2010). By
mapping the b12 structural epitope to the amino acid sequences of
primary gp120 proteins with a range of b12-binding and b12-
neutralization sensitivities, we identiﬁed several polymorphisms at
the gp120–b12 interface associated with sensitivity and resistance to
b12. By comparing the b12 epitope to the overlapping yet distinct
CD4 binding site we were able to identify regions that were
important for b12 resistance that mapped exclusively to the b12
epitope. Our structural studies also illustrate the importance of gp120
structural ﬂexibility for efﬁcient presentation of the b12 epitope.
Together, our results provide new mechanistic insights into the
interaction between physiologically-relevant gp120 proteins and
b12, which may be signiﬁcant for structure-guided approaches to
HIV-1 vaccine design that depend on a thorough knowledge of the
presentation of neutralization epitopes on gp120.Materials and methods:
Cells
293 T cells were cultured in DMEM supplemented with 10%
(vol/vol) fetal calf serum (FCS), and 100 mg of penicillin and
streptomycin per ml. JC53 cells (Platt et al., 1998), were cultured
in DMEM supplemented with 10% (vol/vol) FCS, and 100 mg of
penicillin and streptomycin per ml.
Plasmids
The HIV-1 Envs used in this study were cloned from primary R5
HIV-1 isolates, which have been described in detail previously,
including the clinical characteristics of the subjects from whom they
were isolated (Sterjovski et al., 2007,, 2011,, 2010). The Envs used
were NB2-C1, NB2-C4, NB6-C3, NB6-C4, NB7-C1, NB7-C2, NB8-C2,
NB8-C4, NB23-C2, NB23-C3, NB24-C3, NB24-C4, NB25-C2, NB25-C3,
NB27-C2, and NB27-C3, (Sterjovski et al., 2007,, 2011,, 2010) which
are cloned into the pSVIII-Env expression vector (Gao et al., 1996).
The pCMVDP1DenvpA and pHIV-1Luc plasmids used to generate Env
pseudotyped luciferase reporter viruses have been described pre-
viously (Yang et al., 2005,, 2004,, 2001).
Production and titration of env-pseudotyped luciferase reporter
viruses
Env-pseudotyped, luciferase reporter viruses were produced
by transfection of 293 T cells with pCMVDP1DenvpA, pHIV-1Luc
and pSVIII-Env plasmids using Lipofectamine 2000 (Invitrogen) at
a ratio of 1:3:1, as described previously (Cashin et al., 2011; Gray
et al., 2006; Sterjovski et al., 2007; Yang et al., 2001). Super-
natants were harvested 48 h later, ﬁltered through 0.45 mm ﬁlters
and stored at 80 1C. The TCID50 of virus stocks was determined
by titration in JC53 cells (Platt et al., 1998), as described
previously (Gray et al., 2009; Roche et al., 2011a, 2011b).
Antibodies
The monoclonal antibody IgG1–b12 (b12) (Burton et al., 1991,,
1994) and the polyclonal antibody HIV-Ig have been described
previously (Burton et al., 1991, 1994; Muster et al., 1994; Trkola
et al., 1995, 1996b). The BB10 pooled HIV-1þ sera has been
J. Sterjovski et al. / Virology 432 (2012) 394–404396described previously (Gorry et al., 1999). Goat anti-human Ig
(HþL chain) FITC labeled F(ab’)2 fragment was obtained from
Chemicon (Merck Millipore, Billerica, MA).
Binding assays
Measurement of b12 binding to Env was determined using a
cell-based binding assay that we have described previously
(Sterjovski et al., 2011,, 2010). Brieﬂy, 293 T cells were transfected
with Env expression plasmids using Lipofectamine 2000 (Invitrogen)
according to the manufacturers’ protocol, and stained for surface Env
expression using pooled polyclonal BB10 HIV-1þsera, as described
previously (Sterjovski et al., 2007). In this system, Env typically exists
as monomers of gp120 and uncleaved gp160 (Gorry et al., 2002).
Approximately 2105 293 T cells transfected with each Env expres-
sion plasmid were used in binding reactions. Following pre-incuba-
tion in FACS buffer [phosphate buffered saline (PBS) containing 10%
(vol/vol) FCS and 0.05% (wt/vol) sodium azide] for 1 h on ice, 293 T
cells were washed twice in 1 ml of ice cold FACS buffer and
resuspended in 50 ml of FACS buffer containing 1 mg b12/ml, a
concentration determined empirically to be within the linear range
of binding (data not shown). Cells were incubated on ice for 1 h then
washed twice with ice cold FACS buffer before being resuspended in
50 ml of FACS buffer containing goat anti-human Ig (HþL chain) FITC
labelled F(ab’)2 fragment (1:200 dilution). Following incubation
with the secondary detection antibody for 1 h on ice, cells were
washed twice and resuspended in 150 ml of ice cold PBS containing
4% (wt/vol) paraformaldehyde, and analyzed by ﬂow cytometry as
described previously (Gorry et al., 1999).
Neutralization assays
The ability of b12 and HIV-Ig to neutralize the infectivity of
Env-pseudotyped luciferase reporter viruses was assayed using JC53
cells. Two hundred TCID50 of each Env-pseudotyped luciferase
reporter virus, equating to a multiplicity of infection (MOI) of 0.02,
was incubated with 10-fold increasing concentrations of b12 (0.0005
to 50 mg/ml) or HIV-Ig (1 to 10,000 mg/ml) for 1 h at 37 1C. The virus/
antibody mixtures were then used to inoculate JC53 cells plated in a
96-well plate and incubated overnight at 37 1C. Cells were rinsed
twice with culture medium to remove residual virus inoculum and
incubated a further 48 h at 37 1C. Virus infectivity was then measured
by assaying luciferase activity in cell lysates (Promega, Madison, WI)
according to the manufacturer’s protocol. Negative controls included
mock-infected cells that were incubated with culturemedium instead
of virus, and cells treated with luciferase reporter virus pseudotyped
with the non-functional DKS Env (Etemad-Moghadam et al., 2000).
After subtracting background luciferase activity, the amount of
luciferase activity in the presence of antibody was expressed as a
percentage of the amount produced in control cultures containing no
antibody. The percent inhibition was calculated by subtracting this
number from 100. Data were ﬁtted with a non-linear function, and
ﬁfty- and ninety- percent inhibitory concentrations (IC50 and IC90,
respectively) were calculated by least squares regression analysis of
inhibition curves (Gorry et al., 2007, 2002; Gray et al., 2005).
Computer-aided structural modeling of gp120
Homology models of b12-bound primary gp120 sequences were
prepared using the Build Model protocol of the Discovery Studio suite,
version 1.6 (Accelrys). This approach uses the Modeler algorithm to
generate an atomic model of the target protein from a template
molecule and a sequence alignment. The template-based models are
optimized by iterative cycles of conjugate-gradient minimization
against a probability density function that includes spatial restraints
derived from the template and residue speciﬁc properties (Sali andBlundell, 1993). The crystal structure of gp120 bound to b12was used
as a template for b12-bound models (PDB ID: 2NY7) (Zhou et al.,
2007). Primary gp120 sequences were aligned against the 2NY7
sequence for the b12 models. The V1/V2 and variable loops were
deleted and the V4 variable loop truncated from primary gp120
sequences. Chain breaks were inserted to mirror chain breaks in the
crystal structure. N- and C- termini overhangs were cut using the
modeling protocol. The coordinates for gp120 and the b12 heavy and
light chains were extracted from the 2NY7 crystal structure. Sequence
alignments were generated between 2NY7 gp120 and the primary
gp120 isolates. The sequences for the b12 heavy and light chains
were included as additional polypeptide chains so that the models of
gp120 were constructed as complexes with the b12 heavy and light
chains. To examine mutations in the context of a full-length V4 loop,
additional models were generated for selected gp120 sequences
where the V4 loop was left intact. Once the models were generated,
harmonic constraints were applied prior to optimization using the
Steepest Descent protocol, as we have described recently (Cashin
et al., 2011).Results and discussion
Homology models of primary R5 gp120 proteins bound
to neutralizing antibody b12
To investigate structural alterations in gp120 associated with
sensitivity to b12, predicted three-dimensional structures of 16
well-characterized primary gp120 proteins (Sterjovski et al.,
2007,, 2011,, 2010) in their b12-bound state were generated using
homology modeling. Fig. 1A shows the crystal structure of a
stabilized variant of HXB2 gp120 (grey) in complex with the
heavy and light chains (dark blue and light blue, respectively) of a
b12 Fab fragment (PDB ID: 2NY7) that was used as a template to
generate the b12-bound gp120 models. Primary gp120 model
structures (grey) were superimposed onto the template structure
(blue) (Fig. 1B) and structural similarity to the template crystal
structure was determined by measuring the root mean square
deviation (RMSD) (Table 1). RMSDs ranged from 0.22 A˚ to 0.44 A˚,
indicating a highly conserved core domain. Overall, there was
little deviation between the b12-bound primary gp120 models
and their crystal structure template, indicating a high degree of
structural similarity between the crystal and model structures.
It should be noted however, that since stabilization of gp120 in a
CD4-bound state was required to solve the crystal structure of
gp120 in complex with b12 (Zhou et al., 2007), these structures
represent a gp120 form that exists closer to a CD4-bound state
rather than to the native, unliganded gp120 structure.
Mapping the non-linear b12 epitope on primary gp120 structural
models
We next mapped the three—dimensional b12 epitope on the
amino acid sequence of the primary gp120 proteins. Residues
located at the gp120–b12 interface were identiﬁed using the PISA
computational platform (Krissinel and Henrick, 2007). Fig. 2
shows the molecular surface of the 2NY7 crystal structure
(Fig. 2A) with gp120–b12 interface residues highlighted on both
gp120 and b12 (Fig. 2B). Amino acid sequences at the gp120–b12
interface were extracted from the primary gp120 models and
aligned against the gp120 protein sequence of the 2NY7 crystal
structure (Fig. 2C–I). Interface residues were generally conserved
across all gp120 sequences and overlapped with four regions of
gp120 previously determined to be part of the CD4 binding
domain (Kwong et al., 1998; McCaffrey et al., 2004; Sterjovski
et al., 2011). These regions included the C2 region, the CD4
Table 1
RMSD of gp120 models aligned against the 2NYC crystal structure template.
Primary gp120 model Ca atom RMSD (A˚) a Binding (RMFI)
b
b12 BB10
NB2-C1 0.22 þþþ þþþ
NB2-C4 0.28 þþ þþþ
NB6-C3 0.39 þþþ þþþ
NB6-C4 0.44 þþþ þþþ
NB7-C1 0.29 þþþ þþþ
NB7-C2 0.26 þþþ þþþ
NB8-C2 0.26 þþþ þþþ
NB8-C4 0.31 þþþ þþþ
NB23-C2 0.31 þþþ þþþ
NB23-C3 0.29 þþ þþþ
NB24-C3 0.32  þþþ
NB24-C4 0.33  þþþ
NB25-C2 0.24 þþþ þþþ
NB25-C3 0.28 þþþ þþþ
NB27-C2 0.35 þþþ þþþ
NB27-C3 0.32 þþþ þþþ
Binding was scored as:–(0–50 RMFI), þ (4200 RMFI), þþ (41000 RMFI),
þþþ(42000 RMFI).
a Ca atom RMSD of the entire gp120 model structure was calculated based on
all residues for each model.
b gp120 binding to b12 and the polyclonal HIVþ sera BB10 was analyzed by
ﬂow cytometry and expressed as relative mean ﬂuorescence intensity (RMFI), as
described in Materials and Methods.
Fig. 1. Primary gp120 proteins in complex with b12 Fab. Models of gp120 proteins from primary HIV-1 isolates were generated by homology modeling using a crystal
structure of gp120 bound to a b12 Fab fragment as a template (Zhou et al., 2007) (A). The heavy and light chains of the b12 Fab are shown in dark blue and light blue,
respectively. All of the 16 primary gp120 models were superimposed onto the crystal structure (B); model and crystal structures are shown in Ca stick representation with
primary gp120 models in grey and the crystal structure in blue. The CD4 binding loop is colored magenta and disulﬁde bonds in orange. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
J. Sterjovski et al. / Virology 432 (2012) 394–404 397binding loop motif, the C4 region and the V5 loop. The b12
epitope also spanned regions of gp120 that were not previously
identiﬁed to be involved in CD4 binding, including an additional
residue in C2, residues at the start of V4, and additional residues
in C4. Analysis of the gp120–b12 interface highlighted that while
the b12 epitope encompasses several regions involved in CD4
binding, it also contains regions of gp120 that are distinct from
the CD4 binding site (Bublil et al., 2006; Zhou et al., 2007),
suggesting that the CD4 binding site and b12 epitope are
differentially modulated by amino acid variations at the surface
of the interface. Based on the results of previous studies that have
characterized the inﬂuence of Env alterations on CD4 binding, b12
binding and fusogenicity (Duenas-Decamp et al., 2009; Dunfee
et al., 2006, 2007; Sterjovski et al., 2007, 2011), 5 amino acid
variants at the gp120–b12 interface were identiﬁed and selected
for further study. These included N279D and T283N within the C2
region (Fig. 2D), N362K/Q and Q363P/H/S adjacent to the CD4
binding loop motif (SSGGDPEI) within C4 (Fig. 2E), and N386D in
V4 (Fig. 2F).Polymorphisms within – and adjacent to – the b12 epitope in gp120
associated with b12 binding
Amino acid variants located at the gp120–b12 interface were
then mapped onto the 2NY7 crystal structure (Fig. 3A) to
illustrate their proximity to the b12 epitope. To investigate the
potential of these variants to modulate the efﬁciency of b12
binding to gp120, binding assays were conducted for each of the
primary Envs, the results of which are summarized in Table 1, and
the relative abilities of gp120 to bind b12 was stratiﬁed according
to the presence or absence of each variant (Fig. 3B–F). These
analyses revealed that two amino acid variants, N362 (Fig. 3D)
and Q363 (Fig. 3E), were associated with statistically signiﬁcant
increases in b12 binding. Positive trends were observed for the
presence of N279 (Fig. 3B), T283 (Fig. 3C) and loss of a glycan at
position 386 (Fig. 3F), however these were not statistically
signiﬁcant. Given that the Env proteins present in these binding
assays are likely to contain some uncleaved gp160 as well as
monomeric gp120 (Gorry et al., 2002), and since previous studies
have shown that b12 may recognize monomeric gp120 more
efﬁciently than gp160 (Roben et al., 1994), further biochemical
studies using puriﬁed gp120 may be required to better under-
stand the signiﬁcance of the association between these Env amino
acid variants and b12 binding.
We have previously identiﬁed N362 as being associated with
more efﬁcient cell–cell fusion and enhanced CD4 binding to
gp120 (Sterjovski et al., 2007,, 2011). Glycosylation of N362 could
have a signiﬁcant affect on b12 binding due to its position relative
to the b12 epitope, in particular the CD4 binding loop which is an
important structural element required for the gp120–b12 inter-
action. However, the mechanism by which N362 is associated
with augmented b12 binding is unclear given the absence of
direct interactions with b12.
The gp120 variant Q363 is also located adjacent to the CD4
binding loop. The amide side chain of glutamine has weakly basic
properties, which can act as a H-bond acceptor. However, analysis
of potential interacting partners of Q363 and other amino acids
occurring at this position did not identify any potential contacts
with b12 (data not shown). Absence of an atomic level explana-
tion for N362 or Q363 may indicate that conformation or
ﬂexibility of the CD4 binding loop is likely to be the key to b12
recognition.
The immune response against HIV-1 is continually evolving
over the course of infection, which in turn forces HIV-1 to adapt in
order to escape neutralization (Richman et al., 2003). A study that
examined the emergence of escape virus in response to neutraliz-
ing antibodies reported that neutralization escape mutations
Fig. 2. Predicted b12 contact residues in gp120 structural models and identiﬁcation of b12 epitope polymorphisms. The molecular surface of the 2NY7 crystal structure,
with gp120 (white) shown bound to the heavy (dark blue) and light (light blue) chains of the b12 Fab fragment (A). The gp120–b12 interface was characterized using the
PISA computational platform (Krissinel and Henrick, 2007) (B); the b12 epitope is shown in blue on the molecular surface (B, top left) and ribbon model (B, top right) of
gp120 while the gp120 footprint on the heavy chain of the b12 Fab is shown in grey on the molecular surface (B, bottom left) and ribbon diagram (B, top right) of b12. In
the ribbon diagrams, gp120 and the b12 heavy and light chains are colored as in (A), the CD4 binding loop is colored magenta and residues located within the gp120/b12
interface are shown as ball and stick models. Sequences extracted from primary gp120 models were aligned against the 2NY7 crystal structure sequence (C-I). The
alignments illustrate gp120 residues at the gp120–b12 interface (shaded in grey) located in the C2 (C and D), C3 (E), V4 (F), C4 (G and H) and V5 (I) regions. Boxed residues
indicate the asparagine residues that are within a potential N-linked glycosylated site (PNGS). Blue circles denote residues located within the CD4 binding site (Sterjovski
et al., 2011). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 3. b12 binding studies and amino acid variants located at the gp120–b12 interface. The b12 epitope (grey) and position of amino acid variants (red) displayed on the
molecular surface of the 2NY7 crystal structure of gp120 (white) (A, top). The b12 epitope is also shown as grey molecular surface superimposed onto the ribbon model of
gp120 (A, bottom) with Ca atoms of amino acid variants at position 278, 283, 362, 363 and 386 shown as red space-ﬁlling models and the CD4 binding loop colored
magenta. b12 binding was determined by ﬂow cytometry and values were stratiﬁed according to the absence or presence of amino acid polymorphisms at position 278 (B),
283 (C), 362 (D), 363 (E) and 386 (F) using Prism 5.0 a (Graphpad Software, San Diego CA). Box plots represent upper and lower quartiles and median scores, and whiskers
represent minimum and maximum values and were constructed from mean values of duplicate experiments with each Env. The data shown are representative of
2 independent experiments. P values were calculated using an unpaired T test; values less than 0.05 were considered statistically signiﬁcant. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
J. Sterjovski et al. / Virology 432 (2012) 394–404 399occurred predominantly in N-linked glycosylation sites, giving rise
to the ‘‘evolving glycan shield’’ model of HIV-1 escape from
immune selection pressures (Wei et al., 2003). Changes in the
glycosylation pattern led to changes in glycan packing that
allowed neutralizing antibody escape without inhibiting interac-
tions with entry receptors. Therefore, shifts in glycosylation
pattern have the potential to modulate b12 antibody binding.
The N386D gp120 variant is associated with HIV-1 dementia and
results in loss of a potential glycosylation site that was associated
with reduced CD4 dependence and greater exposure of the CD4
binding site (Dunfee et al., 2007). While D386 had a minor effect
on reduced CD4 afﬁnity in this study, restoring the glycosylation
site at this position resulted in a 8-fold increase in resistance to
neutralisation by b12. More recently, glycosylation at position 386
was shown to be involved in immune evasion (Sanders et al.,
2008). Interestingly, we show here that the V4 region, which
contains the N386D variant, is involved in the formation of the
gp120–b12 interface (Fig. 2F) but not the CD4 interface (Sterjovski
et al., 2011). This may explain why D386 affected CD4 dependence
to a small degree compared to the dramatic affect it had on
sensitivity to neutralization by b12 (Dunfee et al., 2007).
Amino acid variants T283N and N279D have previously been
associated with enhanced gp120–CD4 interactions. N283 is asso-
ciated with enhanced CD4 afﬁnity and macrophage tropism by
brain-derived Envs (Duenas-Decamp et al., 2009; Dunfee et al.,
2006) via the formation of an additional hydrogen bond between
gp120 and Q40 of CD4 (Dunfee et al., 2006). However, mutagen-
esis studies suggest that its affect on b12 sensitivity may becontext dependent (Duenas-Decamp et al., 2008). We have pre-
viously shown that the N279D mutation is associated with
enhanced CD4 interaction and macrophage tropism that is most
likely due to the introduction of a salt-bridge with K31 of CD4
(Sterjovski et al., 2011). In both cases, the variant associated with
less efﬁcient gp120–b12 binding has previously been linked to
more efﬁcient gp120–CD4 binding, further illustrating the oppos-
ing forces on CD4 and b12 binding in this region of Env.
Characterization of b12-resistant gp120 proteins
Two Env clones from NB24 demonstrated very low binding to
b12 despite robust expression of Env on the surface of 293 T cells
(Table 2). There is no signiﬁcant difference between NB24 and
NB8 Envs in binding to human recombinant soluble CD4
(Sterjovski et al., 2011), suggesting that differences between these
Envs are restricted to the part of the b12 epitope that does not
overlap the CD4 binding domain. Since b12 binding could affect
sensitivity to neutralization of HIV-1 by b12, we next performed
virus neutralization assays using luciferase reporter viruses pseu-
dotyped with Envs that demonstrate very low (NB24-C3, NB24-
C4) or very high (NB8-C2, NB8-C4) binding to b12, and the control
R5 strains ADA and JR-CSF. An alternative potential outcome,
however, is that the binding properties of monomeric gp120 to
b12 may not necessarily predict the sensitivity of trimeric Env
complexes that are present on the surface of virions to antibody
neutralization sensitivity (Moore et al., 1995; Pantophlet et al.,
2003; Parren et al., 1998; Roben et al., 1994; Sattentau and Moore,
J. Sterjovski et al. / Virology 432 (2012) 394–4044001995). For example, conformational differences in the gp120 loop
regions when they are part of the trimeric Env complex may
affect the accessibility of b12 to its gp120 binding site, even
though those regions are not part of the b12 epitope. The
neutralization curves are shown in Fig. 4, and the IC50 and IC90
values are summarized alongside the b12 binding data (Table 2).
Viruses pseudotyped with Envs from NB24 were resistant to
neutralization by b12 (Fig. 4A), with neutralization curves failing
to reach 50% inhibition at the highest concentration of b12.
However, viruses pseudotyped with Envs from NB8 and the
control R5 strains reached 100% neutralization by b12, with IC50
and IC90 values ranging between 0.9–2.9 and 3.8–5.5 mg of
b12/ml, respectively (Table 2). In contrast, all the Env pseudo-
types were readily neutralized by HIV-Ig (Fig. 4B).
Together, our results suggest that resistance to neutralization
by b12 of NB24 Env clones is speciﬁc to the part of the b12
epitope that does not overlap the CD4 binding site. Our ﬁndings
are consistent with those of previous studies of gp120 from
different HIV-1 subtypes, which found that substitutions within
the CD4 binding loop of gp120 as well as substitutions proximal
to- but not part of the CD4 binding loop, can mediate resistance to
neutralization by b12 (Wu et al., 2009). The latter substitutions
permitted b12-resistant viruses to maintain strong CD4 binding
capacity, similar to the NB8 and NB24 Envs studied here whichTable 2
Comparison of b12 binding and neutralization.
Binding (RMFI) Neutralization
b12 (mg/ml) HIV-Ig (mg/ml)
R5 Env b12 BB10 IC50 IC90 IC50 IC90
Mock – – n/a n/a n/a n/a
ADA þþþ þþþ 1.3 3.9 1.4 2.2
JRCSF þþþ þþþ 0.9 3.8 0.6 1.3
NB24-C3 – þþþ 450 450 1.0 2.4
NB24-C4 – þþþ 450 450 0.8 2.0
NB8-C2 þþþ þþþ 1.1 3.85 0.6 1.7
NB8-C4 þþþ þþþ 1.3 3.92 0.3 1.2
gp120 binding to b12 and BB10 was analyzed by ﬂow cytometry and expressed
as relative mean ﬂuorescence intensity (RMFI), as described in Materials and
Methods. Binding was scored as:–(0–50 RMFI), þ (4200 RMFI), þþ (41000
RMFI), þþþ (42000 RMFI). Neutralization sensitivities to b12 and HIV-Ig were
determined as described in Materials and Methods.
Fig. 4. Neutralization sensitivity of R5 Envs with low or high b12 binding. Luciferase
binding (NB24-C3 and NB24-C4) or high b12 binding (NB8-C2 and NB8-C4) were prod
were performed using b12 (A) or HIV-Ig (B) and data were ﬁtted with a non-linear fu
means of triplicates, and the error bars represent standard deviations. The results showdiffered in their b12 binding and neutralization sensitivities
(Table 2), but maintained approximately equivalent levels of
CD4 binding capacity (Sterjovski et al., 2011). Resistance of the
NB24 Env clones to neutralization by b12 therefore provides a
rare opportunity to probe the mechanisms of b12 resistance in
isolation.
Structural features of gp120 associated with b12 resistance
To determine the structural features of gp120 associated with
resistance or sensitivity to neutralization by b12, we next pro-
duced homology models of the b12-resistant clone NB24-C3
(Fig. 5A) and the b12-sensitive clone NB8-C2 (Fig. 5B) to map
the b12 epitope in the context of the CD4 binding site. Residues
located at the gp120–b12 interface (see Fig. 2) or those located
within the CD4 binding site that were identiﬁed in our previous
studies (Sterjovski et al., 2011), were shown as space-ﬁlling
models on the gp120 ribbon structure and colored light blue or
dark blue, respectively. Residues that overlap both the b12 and
CD4 binding sites were colored magenta. Sequences extracted
from the NB24-C3 and NB8-C2 model structures were aligned
against the 2NY7 crystal structure sequence and colored as above
(Fig. 5C). Since polymorphisms that involve the loss or shift of
potential N-linked glycosylation sites (PNGS) are often associated
with sensitivity to b12 neutralization, PNGS that differed between
NB24-C3 and NB8-C2 were examined on the model structures
(white space-ﬁlling models, Fig. 5A and B, right panels).
One striking difference was the presence of the N386 glycan in
the V4 loop of NB24-C3, which also mapped to the b12 epitope.
While NB8-C2 contained PNGS in V4, they were not part of the
b12 epitope. NB24-C3 also contained an insertion of a PNGS at
position 460 located at the start of the V5 loop that was
not present in NB8-C2. While N460 may contribute to exposure
of residues in the CD4 and b12 binding sites, the location
of N386 exclusively within the b12 epitope may contribute to
the speciﬁc resistance to neutralization by b12 displayed by NB24
Env clones.
Amino acid alterations in the gp120 CD4 binding loop associated
with b12 resistance
Other signiﬁcant mutations in NB24 Env clones included
amino acid changes located within or adjacent to the CD4 binding
loop (Fig. 6). Close up views of the NB24-C3 and NB8-C2 CD4reporter viruses pseudotyped with primary gp120 proteins exhibiting low b12
uced and quantiﬁed as described in Materials and Methods. Neutralization assays
nction using Prism 5.0 a (Graphpad Software, San Diego CA). The data shown are
n are representative of 3 independent experiments.
Fig. 5. Comparison of the b12-resistant NB24-C3 Env structure to the highly sensitive NB8-C2 Env structure in the context of the CD4 binding site and PNGS.
Residues on NB24-C3 (A) and NB8-C2 (B) gp120 models (grey ribbons) located at the b12 and CD4 interface are shown as space-ﬁlling models and colored according to
whether they are found exclusively within the b12 epitope (light blue), the CD4 binding site (dark blue) or whether they overlap both (magenta). Interface residues were
determined as those located within 4A˚ of the ligand. Potential N-linked glycosylation sites colored white. (C) Multiple sequence alignment of sequences extracted
from the NB24-C3 and NB8-C2 model structures were aligned against the 2NY7 crystal structure sequence and residues were colored as in panels A and B. Loop regions
deleted from the crystal and model structures are labeled in parentheses. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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between the two Envs shown in stick representations and colored
according to polarity. Amino acids P363, P364 and M373 in the
N-terminal region of the NB24-C3 CD4 binding loop result in a
more structurally rigid and nonpolar loop structure (Fig. 6B, top
left) compared to the CD4 binding loop of NB8-C2 (Fig. 6B, right),
which contains amino acids with ﬂexible and polar side chains.
The inherent conformational ﬂexibility of gp120 is critical for
antibody recognition (Kwong et al., 2002; Zhou et al., 2007).
Substitutions of highly conserved residues in the CD4 binding
loop with conformationally rigid amino acids such as proline may
therefore contribute to the neutralization resistant phenotype of
NB24 Env clones. In addition, analysis of potential interacting
partners showed that the S364P change in NB24-C3 resulted in
the loss of a hydrogen bond between gp120 and Y98 of b12
(Fig. 6B, lower left), which may contribute to the low afﬁnity
binding of b12 for NB24 clones. A serine at this position is highly
conserved amongst the gp120 clones studied, with NB24 clones
being the only sequences containing a proline at this position.
Disruptions in hydrogen bond patterns in addition to the presence
of inﬂexible and nonpolar residues in the CD4 binding loop of
NB24 clones may restrict interactions with b12 and contribute to
the resistant phenotype.
Comparisons between the CD4 binding loop of the highly
neutralization resistant Env clones from NB24 and b12 sensitive
clones from NB8 revealed that the serine to proline mutation at
position 364 in NB24 Envs resulted in the loss of a hydrogen bond
with Y98 in b12. Reduced ﬂexibility as a result of the P363–P364sequence in NB24 gp120 proteins may also affect binding of b12
to the CD4 binding loop. Both CD4 and b12 bind to the CD4
binding loop motif (Zhou et al., 2007). However, b12 uses all three
complementarity determining region (CDR) heavy chain loops to
tightly grasp the entire loop. It is therefore possible that muta-
tions that limit the ﬂexibility of the CD4 binding loop could
signiﬁcantly affect binding of the three b12 heavy chain loops.
However, other structural features could also contribute to the
highly b12 resistant phenotype of NB24 gp120 proteins. These
features may be hidden in variable loops deleted from the original
crystal structure on which the models were based (Zhou et al.,
2007). The V1, V2 and V3 variable loops of gp120 are thought to
be in close proximity to the CD4 binding site and movements of
these loops have been associated with exposure of the coreceptor
binding site upon CD4 binding (Chang et al., 2005; Dey et al.,
2007; Steffens and Hope, 2004; Wyatt et al., 1998). Results from
previous studies (Zwick et al., 2003) suggest that the V1, V2 and
V3 loops, as well as C4 residues that form part of the bridging
sheet, are in close enough proximity to one another and to the
CD4 binding site to be involved in a single discontinuous epitope
for the neutralizing antibody 4KG5. In addition, alterations of the
V1, V2 and V3 loops have been previously shown to differentially
modulate the response to antibodies directed against the CD4
binding site (Ly and Stamatatos, 2000; Nabatov et al., 2004).
This highlights the possibility that gp120 variable loops excluded
from the models studied here and from the available crystal
structure (Zhou et al., 2007) may have signiﬁcant roles in the
ability of primary gp120 proteins to bind CD4 and b12, and may
Fig. 6. Structural features of gp120 associated with resistance to neutralization by b12.
gp120 protein structures (A, grey ribbon) of the b12 resistant clone NB24-C3 (left) and
b12-sensitive clone NB8-C2 (right panels) showing the V4 loop (blue), V5 loop (green)
and CD4 binding loop (magenta). The Ca atoms of cysteine residues involved in
disulﬁde bonds in the V4 loop are shown as orange space-ﬁlling models and the
disulﬁde bond itself is shown in orange stick representation. Sequence alignment
showing amino acid differences in the CD4 binding loop region of gp120 (B), also
illustrated on the NB24-C3 (B, top left) and NB8-C2 (B, top right) protein models
coloured as in (A), with the b12 ribbon shown in blue (CDR H2 loop hidden). Close up
view of the CD4 binding loop showing the position of P364 in NB24-C3 clone
(B, bottom left) and the hydrogen bond between S364 and Y98 on the b12 CDR H3
loop in NB8-C2 (B, bottom right). Sequence alignment of the V4 loop (C) showing the
location of additional cysteine residues in NB24-C3 that form an additional disulﬁde
bond in the model structure (C, left), compared to the single disulﬁde bond in NB8-C3
(C, right). N386 is shown as a white space-ﬁlling model and disulﬁde bondsmodeled as
described in panel A. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
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differences seen in the efﬁciency of CD4 use and sensitivity to
neutralization by b12.An additional disulﬁde bond in the gp120 V4 loop is associated
with b12 resistance
The b12 resistant Env clones from NB24 also contain an
additional disulﬁde bond in the gp120 V4 loop via the introduc-
tion of two cysteine residues at positions 395 and 410 (Fig. 6C, left
panel), in addition to the highly conserved cysteine residues at
position 385 and 418 at the base of the loop. Analysis of 177
gp120 sequences published in the 2009 Los Alamos HIV Sequence
Compendium revealed that the presence of an additional disulﬁde
bond in the V4 loop occurred in only 9% of sequences (14 out of
177), suggesting that this is a relatively uncommon structural
feature in HIV-1 gp120 proteins. An additional disulﬁde bond in
the V4 loop, which contains residues that are involved in forma-
tion of the b12 epitope, including the immunomodulatory glycan
N386, is likely to affect the conformational ﬂexibiliy of the b12
recognition site.Conclusions
In summary, the three-dimensional models of b12-bound
primary R5 gp120 proteins studied here provided valuable
insights into the structural determinants of an important HIV-1
neutralization epitope. By mapping the b12 structural epitope to
the amino acid sequences of primary gp120 proteins with a range
of b12-binding and b12-neutralization sensitivities, we identiﬁed
polymorphisms at the gp120–b12 interface associated with sen-
sitivity and resistance to b12. By comparing the b12 epitope to
the overlapping yet distinct CD4 binding site we were able to
identify regions that were important for b12 resistance that
mapped exclusively to the b12 epitope. Furthermore, our results
highlight the importance of gp120 structural ﬂexibility for efﬁ-
cient presentation of the b12 epitope. Together, our results
provide new mechanistic insights into the interaction between
physiologically-relevant R5 gp120 proteins and b12, which may
be signiﬁcant for structure-guided approaches to HIV-1 vaccine
design that depend on a thorough knowledge of the presentation
of neutralization epitopes in gp120.Acknowledgements
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